McKesson (NYSE:MCK) Sets New 12-Month High on Earnings Beat

McKesson Corporation (NYSE:MCK)’s stock price reached a new 52-week high on Thursday following a stronger than expected earnings report. The stock traded as high as $964.94 and last traded at $958.92, with a volume of 586810 shares traded. The stock had previously closed at $822.00.

The company reported $9.34 EPS for the quarter, topping the consensus estimate of $9.19 by $0.15. McKesson had a negative return on equity of 303.62% and a net margin of 1.09%.The business had revenue of $106.16 billion for the quarter, compared to the consensus estimate of $105.98 billion. During the same period in the previous year, the company posted $8.03 earnings per share. The company’s revenue for the quarter was up 11.4% compared to the same quarter last year. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS.

McKesson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 1st. Shareholders of record on Monday, March 2nd will be paid a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date is Monday, March 2nd. McKesson’s dividend payout ratio (DPR) is currently 9.43%.

Key Headlines Impacting McKesson

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: Q3 earnings beat and revenue growth — McKesson reported quarterly EPS above consensus and revenue up ~11.4% year‑over‑year, driven by higher gross profit and operating profit expansion. Business Wire: Q3 Results & Guidance
• Positive Sentiment: Raised FY‑2026 adjusted EPS guidance — Management increased full‑year adjusted EPS to $38.80–$39.20, signaling confidence in specialty drug and oncology/biopharma services growth that underpins margin outlook. Reuters: Boosts 2026 Profit Forecast
• Positive Sentiment: Market reaction — Street enthusiasm around the beat + guidance lift sent shares to multi‑year/all‑time highs and a strong intraday jump as analysts and investors re‑rate growth expectations. Investing.com: Stock Hits All‑Time High
• Neutral Sentiment: Analyst actions mixed — Some firms nudged price targets higher (Wells Fargo, Mizuho) but maintained neutral/equal‑weight stances, so analyst moves are not uniformly bullish. Zacks: Broker View on MCK
• Negative Sentiment: Operational cash‑flow weakness and balance‑sheet items — reporting flagged weaker operating cash flow versus last year and higher total liabilities, which could temper valuation upside if cash conversion doesn’t improve. Insider selling was also noted. QuiverQuant: EPS Beat but Weak Cash Flow

Analyst Ratings Changes

MCK has been the subject of several analyst reports. UBS Group raised their price target on shares of McKesson from $920.00 to $980.00 and gave the company a “buy” rating in a research report on Thursday, November 6th. Morgan Stanley reissued an “overweight” rating and issued a $966.00 target price on shares of McKesson in a report on Thursday, January 29th. Wall Street Zen downgraded McKesson from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. Wells Fargo & Company lifted their price objective on McKesson from $914.00 to $925.00 and gave the stock an “equal weight” rating in a report on Thursday. Finally, Zacks Research lowered McKesson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 25th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $918.93.

Insiders Place Their Bets

In other McKesson news, EVP Thomas L. Rodgers sold 276 shares of the firm’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $816.18, for a total value of $225,265.68. Following the transaction, the executive vice president directly owned 2,268 shares of the company’s stock, valued at approximately $1,851,096.24. This trade represents a 10.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.08% of the company’s stock.

Institutional Investors Weigh In On McKesson

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Sequent Planning LLC grew its position in McKesson by 10.6% during the fourth quarter. Sequent Planning LLC now owns 1,577 shares of the company’s stock valued at $1,294,000 after buying an additional 151 shares during the period. TD Private Client Wealth LLC grew its position in shares of McKesson by 19.2% during the 4th quarter. TD Private Client Wealth LLC now owns 2,396 shares of the company’s stock valued at $1,965,000 after acquiring an additional 386 shares during the period. Arrow Financial Corp purchased a new stake in shares of McKesson in the 4th quarter worth $814,000. Tucker Asset Management LLC bought a new position in McKesson in the 4th quarter worth $71,000. Finally, Mission Wealth Management LP raised its holdings in McKesson by 2.1% in the 4th quarter. Mission Wealth Management LP now owns 2,032 shares of the company’s stock worth $1,667,000 after purchasing an additional 41 shares during the period. Hedge funds and other institutional investors own 85.07% of the company’s stock.

McKesson Price Performance

The company has a 50-day moving average of $827.03 and a two-hundred day moving average of $777.93. The company has a market capitalization of $118.41 billion, a PE ratio of 27.59, a P/E/G ratio of 1.35 and a beta of 0.40.

About McKesson

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.